AstraZeneca Collaborates with AI Biologics Firm for Cancer Drug Development
Pharmaceutical company AstraZeneca has partnered with AI biologics company BenevolentAI to develop a cancer drug. The collaboration will leverage BenevolentAI's artificial intelligence technology to identify and validate new drug targets for AstraZeneca's oncology research. The partnership aims to accelerate the discovery and development of potential cancer treatments.